ArticlePituitary2016
A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion.
Article in Pituitary, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.International journal of molecular sciences · 2023Pooled it
- The periphery of pituitary macroadenoma expressed higher invasive capability: the importance of clinical implication.Discover oncology · 2025Article
- Recombinant Human Endostatin Suppressed the Biological Behavior of Human Umbilical Vein Endothelial Cells Under Hypoxic and Hypoxic/Starvation Conditions In Vitro.Analytical cellular pathology (Amsterdam) · 2025Article
- Crosstalk between Endothelial Cells and Tumor Cells: A New Era in Prostate Cancer Progression.International journal of molecular sciences · 2023Review
- MRI and Trouillas' grading system of pituitary tumors: the usefulness of T2 signal intensity volumetric values.Neuroradiology · 2023Article
- Expression of the angiogenesis markers endocan in Cushing's syndrome due to cortisol producing adenoma.Endocrine · 2023Article
- Predictive Value of Blood Markers in Nonfunctional Pituitary Adenomas using Artificial Neural Network.Advanced biomedical research · 2023Article
- Correlation Analysis of Magnetic Resonance Imaging Characteristics and Prognosis of Invasive Pituitary Adenomas in Neurosurgery Hospitals.Journal of healthcare engineering · 2022Article
- Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach.Frontiers in oncology · 2021Review
- Screening lncRNAs with diagnostic and prognostic value for human stomach adenocarcinoma based on machine learning and mRNA-lncRNA co-expression network analysis.Molecular genetics & genomic medicine · 2020Article
- Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.Endocrine · 2020Article
- Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours.Endocrine · 2020Article
- The Pituitary Tumors and Their Tumor-Specific Microenvironment.Advances in experimental medicine and biology · 2020Article
- Endothelial cell-specific molecule-1 as an invasiveness marker for pituitary null cell adenoma.BMC endocrine disorders · 2019Article
- Endocan as a marker of microvascular inflammation in kidney transplant recipients.Scientific reports · 2019Article
- Decreased BMP-7 and p-Smad1/5/8 expression, and increased levels of gremlin in hepatocellular carcinoma.Oncology letters · 2018Article
- Serum endocan levels before and after surgery on low-grade gliomas.Surgical neurology international · 2017Article
- Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma.Oncotarget · 2016Article
- Expressions of Endocan in Patients with Meningiomas and Gliomas.Disease markers · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePituitary adenomas are benign neoplasms that display invasive behavior-a characteristic traditionally associated with malignancy-through an ill-defined mechanism. The role of angiogenesis-related molecules in this pathological condition remains perplexing. Our purpose is to assess the impact of endocan (endothelial cell specific molecule-1, ESM-1), CD34 and CD105 on pituitary adenoma invasion.
methodsIn this study, immunohistochemical analyses for endocan, CD34 and CD105 were performed on paraffin-embedded samples of 66 pituitary adenomas, five normal pituitaries, and five primary hepatic carcinomas. Knosp tumor grades based on magnetic resonance imaging coronal scanning were used to assess the invasiveness of each sample. The associations between endocan expression, CD34/CD105-positive microvessel densities (MVDs), and Knosp tumor invasion grades were evaluated.
resultsThese results showed that endocan protein expression in tumor cells (TCs) was higher than that in endothelial cells (ECs) and strongly correlated with Knosp grades (P < 0.001, Spearman's r = 0.616). Moreover, while endocan-positive TCs localized around the blood vessels in adenomas with higher Knosp grades, no significant association was found between CD34/CD105-MVDs and Knosp grades (CD34: P = 0.256, r = 0.142; CD105: P = 0.183, r = 0.166). Normal pituitary seemed to exhibit lower endocan expression and contained more CD34/CD105-MVDs than pituitary adenomas.
conclusionEndocan expresses in both TCs and ECs of pituitary adenoma. Endocan overexpression in TCs more accurately reflects invasiveness compared to that of CD34/CD105-MVDs and that angiogenesis may not be the primary driver of endocan-medicated pituitary adenoma invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.